NORTH AMERICA POSTPARTUM HAEMORRHAGE TREATMENT DEVICE MARKET FORECAST 2018-2026

NORTH AMERICA POSTPARTUM HAEMORRHAGE TREATMENT DEVICE MARKET FORECAST 2018-2026

  • August 2018 •
  • 69 pages •
  • Report ID: 5484937 •
  • Format: PDF
KEY FINDINGS
North America is a leader in the global postpartum haemorrhage (PPH) treatment devices market. By the end of the forecast period of 2018-2026, the market is expected to maintain its supremacy by exhibiting a CAGR of 4.89%. The expanding occurrence of obesity is driving the PPH risks in the region, which in turn is believed to propel the demand for PPH treatment devices in North America.

MARKET INSIGHTS
The PPH treatment equipment manufacturers are supported by complex healthcare facilities in North American geographies like Mexico, Canada, and the U.S. Presence of a well-established pharmaceutical market and the growing investment in the postpartum haemorrhage research and development activities have resulted in the expanding share of the U.S. market all through the North American region. Additionally, the growing prevalence of obesity and hypertension in the North American market is fueling the PPH treatment device market growth. However, the stringent government regulation and regulatory approval for the postpartum haemorrhage treatment devices market being strategically imposed by the FDA are acting as a major restricting factor for the sustainable long-term growth of the PPH market.

COMPETITIVE INSIGHTS
Companies like Becton Dickinson and Company, Teleflex Incorporated, Cook Medical Inc, C.R.BardInc, Program for Appropriate Technology in Health (PATH), 3rd Stone Design Inc, GE Healthcare, Bactiguard AB, Utah Medical Products Inc and ZoexNiasg are operating in this region.